Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Prostatic Neoplasms
Interventions: JNJ-75229414, Bridging Therapy; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more

Conditions: Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Interventions: Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, Radiation Therapy, Recombinant Interferon Beta; Drug · Other · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Subject
Interventions: Broccoli Sprout Extract (BSE); Drug
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Monitor Adverse Events
Interventions: Anti-PSMA Designer T Cells; Drug
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 15
States / cities: Duarte, California • Irvine, California • San Francisco, California + 11 more

Conditions: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Interventions: CART22 cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Graft Versus Host Disease
Interventions: donor regulatory T lymphocytes, laboratory biomarker analysis; Biological · Other
Lead sponsor: Everett Meyer; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection; Biological · Drug · Radiation + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Stage IV Melanoma
Interventions: Cyclophosphamide, Fludarabine, Lifileucel, Pembrolizumab, Therapeutic Conventional Surgery; Drug · Biological · Procedure
Lead sponsor: Richard Wu; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Relapsed or Refractory Classical Hodgkin Lymphoma
Interventions: Sabestomig (AZD7789); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 101 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more

Conditions: Cytopenia
Interventions: Emapalumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions: cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thrombocytopenia
Interventions: Avatrombopag; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
Interventions: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more

Conditions: Lymphomas, B-cell Lymphomas
Interventions: JV-213, Leukapheresis; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia (AML), Cancer
Interventions: Venetoclax, Azacitidine, Best Supportive Care (BSC); Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma
Interventions: LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C), LMP2 CTLs (ALSCER - Group A), LMP2 CTLs (ALSCER - Group B), LMP2 CTLs (ALSCER - Group C), LMP1/2 CTLs (ALCI - Expansion - Group A), LMP1/2 CTLs (ALCI - Expansion Group B), LMP1/2 CTLs (ALCI - Expansion Group C); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide; Drug · Other
Lead sponsor: John Reneau; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes
Interventions: ORCA-T; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions: Ipilimumab, Nivolumab, VX15/2503, Surgery; Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HTLV-I Infection, Tropical Spastic Paraparesis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Medullary Thyroid Cancer, Recurrent Thyroid Gland Medullary Carcinoma
Interventions: single dose of CART-GFRa4 cells, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsed, Refractory Multiple Myeloma
Interventions: RAPA-201 Autologous T cells; Biological
Lead sponsor: Rapa Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: pTVG-HP with rhGM-CSF; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Evaluation of Patients With HAM/TSP

GFRα4 CAR T Cells in MTC Patients

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer